Spectrum Planning & Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Spectrum Planning & Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$220K	Buy	+3,522	New	+$195K	0.31%	45
2023 Q3	–	Sell	-3,684	Closed	-$207K	–	45
2023 Q2	$207K	Buy	+3,684	New	+$209K	0.31%	39
2022 Q4	–	Sell	-3,816	Closed	-$249K	–	42
2022 Q3	$249K	Sell	3,816 -95	-2%	-$6.88K	0.25%	45
2022 Q2	$238K	Sell	3,911 -1,034	-21%	-$60.8K	0.25%	36
2022 Q1	$310K	Hold	4,945	–	–	0.28%	34
2021 Q4	$375K	Buy	4,945 +450	+10%	+$39.3K	0.34%	36
2021 Q3	$503K	Sell	4,495 -77	-2%	-$9.67K	0.49%	34
2021 Q2	$740K	Sell	4,572 -103	-2%	-$12.5K	0.71%	29
2021 Q1	$570K	Buy	4,675 +100	+2%	+$15.1K	0.59%	30
2020 Q4	$700K	Buy	+4,575	New	+$541K	0.75%	28

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Spectrum Planning & Advisory Services's CRSP Position: Q4 2023 in Review

Spectrum Planning & Advisory Services opened a new position in CRISPR Therapeutics (CRSP) in Q4 2023: 3,522 shares worth $220K. The stake represents 0.31% of the portfolio and ranks #45 among its holdings. This is a return to the name: Spectrum Planning & Advisory Services previously reported a position in CRSP as recently as Q2 2023.

Spectrum Planning & Advisory Services first reported a position in CRSP in Q4 2020 and has held it in 10 quarters since. The position peaked at $740K in Q2 2021. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Spectrum Planning & Advisory Services held 3,522 shares of CRISPR Therapeutics worth $220K as of Q4 2023.
CRISPR Therapeutics was a new Spectrum Planning & Advisory Services position in Q4 2023.
CRISPR Therapeutics made up 0.31% of Spectrum Planning & Advisory Services's portfolio in Q4 2023, its #45 holding.
Spectrum Planning & Advisory Services first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 10 quarters since.
Spectrum Planning & Advisory Services's CRISPR Therapeutics position peaked at $740K in Q2 2021.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Spectrum Planning & Advisory Services's 13F filing for Q4 2023, filed 18 Jan 2024.